ArticleEuropean journal of nuclear medicine and molecular imaging2022
A novel
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Therapeutic targeting of the cGAS-STING pathway in human disease.The Journal of clinical investigation · 2026Review
- Development and Validation of a Multicyclic Peptide Targeting PD-L1 for Radiotheranostics.ACS medicinal chemistry letters · 2026Article
- Activating protein kinases to treat diseases: Current understanding and future challenges.Acta pharmaceutica Sinica. B · 2026Review
- Macromolecular Diamidobenzimidazole Conjugates Can Activate Stimulator of Interferon Genes.Journal of the American Chemical Society · 2025Article
- Development of STING probes and visualization of STING in multiple tumor types.European journal of nuclear medicine and molecular imaging · 2025Article
- STING-targeted PET imaging: unveiling tumor immunogenicity post-chemotherapy in colorectal cancer.European journal of nuclear medicine and molecular imaging · 2024Article
- Preclinical Evaluation ofACS pharmacology & translational science · 2024Article
- Preclinical study and first-in-human imaging of [European journal of nuclear medicine and molecular imaging · 2024Article
- STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy.European journal of nuclear medicine and molecular imaging · 2024Article
- Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies.Cancer biology & medicine · 2024Review
- An ultra-small bispecific protein augments tumor penetration and treatment for pancreatic cancer.European journal of nuclear medicine and molecular imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStimulator of interferon genes (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study aimed to develop a novel
methodsAn analog of the STING agonist NOTA-DABI was synthesized and labeled with
results[
conclusionThis proof-of-concept study demonstrated a STING-binding radioligand for PET imaging, which could be used as a potential companion diagnostic tool for related STING-agonist therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.